Altimmune
Altimmune

Altimmune

Biotechnology
WebsiteInvestor RelationsSEC
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

$412.4M

Market Cap • 10/23/2026

2005

(21 years)

Founded

2005

(21 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,9

P/S

13302,5

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,4

EPS

—

Market Cap

Market Cap

412,4M

EV

120,8M

EV/Revenue

3896,7

EV/EBITDA

-1,2

EV/EBIT

-1,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-94,8%

Total Yield

-94,8%

Payout

0%

Retained Earnings

-694,9M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

220052%

Capex/Revenue

174,2%

Capex/D&A

54,5%

Capex/OCF

-0,1%

SBC/OCF

—

% PPE

0%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-65,4%

CAGR Op. Income 5Y

7,8%

CAGR Net Income 5Y

6,2%

CAGR EPS 5Y

-15,5%

CAGR OCF 5Y

4,5%

Leverage

N.D./EBITDA

2,9

Debt/Equity

0%

Current Ratio

26,8

Quick Ratio

26,4

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium